Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication.
Consecutive missed doses may differentially impact the efficacy of antiretroviral therapy associated with the use of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) and a ritonavir-boosted protease inhibitor (PI). In a cohort of 72 subjects receiving a boosted PI, average adherence to dosage was a better predictor of human immunodeficiency virus (HIV) replication than was the duration or frequency of treatment interruption. In contrast with an NNRTI, consecutive missed doses of a boosted PI did not emerge as a major risk factor for HIV replication.
Parienti
Jean-Jacques
JJ
Department of Clinical Research and Biostatistics, Côte de Nacre University Hospital, Caen F-14033, France.
Ragland
Kathleen
K
Lucht
Frédéric
F
de la Blanchardière
Arnaud
A
Dargère
Sylvie
S
Yazdanpanah
Yazdan
Y
Dutheil
Jean-Jacques
JJ
Perré
Philippe
P
Verdon
Renaud
R
Bangsberg
David R
DR
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood*; D019562:Viral Load; D016903:Drug Monitoring
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral